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Proteasome stress sensitizes 
malignant pleural mesothelioma 
cells to bortezomib-induced 
apoptosis
Fulvia Cerruti1, Genny Jocollè2, Chiara Salio1, Laura Oliva3, Luca Paglietti1, Beatrice 
Alessandria1, Silvia Mioletti1, Giovanni Donati4, Gianmauro Numico5, Simone Cenci  3 & 
Paolo Cascio1
Based on promising results in preclinical models, clinical trials have been performed to evaluate the 
efficacy of the first-in-class proteasome inhibitor bortezomib towards malignant pleural mesothelioma 
(MPM), an aggressive cancer arising from the mesothelium of the serous cavities following exposure to 
asbestos. Unexpectedly, only minimal therapeutic benefits were observed, thus implicating that MPM 
harbors inherent resistance mechanisms. Identifying the molecular bases of this primary resistance 
is crucial to develop novel pharmacologic strategies aimed at increasing the vulnerability of MPM to 
bortezomib. Therefore, we assessed a panel of four human MPM lines with different sensitivity to 
bortezomib, for functional proteasome activity and levels of free and polymerized ubiquitin. We found 
that highly sensitive MPM lines display lower proteasome activity than more bortezomib-resistant 
clones, suggesting that reduced proteasomal capacity might contribute to the intrinsic susceptibility 
of mesothelioma cells to proteasome inhibitors-induced apoptosis. Moreover, MPM equipped with 
fewer active proteasomes accumulated polyubiquitinated proteins, at the expense of free ubiquitin, 
a condition known as proteasome stress, which lowers the cellular apoptotic threshold and sensitizes 
mesothelioma cells to bortezomib-induced toxicity as shown herein. Taken together, our data suggest 
that an unfavorable load-versus-capacity balance represents a critical determinant of primary apoptotic 
sensitivity to bortezomib in MPM.
The 26S proteasome is an ATP-dependent protease complex abundantly expressed in eukaryotic cells, respon-
sible for the regulated hydrolysis of most cellular proteins1. The 26S is a multi-subunit enzyme consisting of a 
20S particle, where polypeptides get hydrolyzed, associated with the 19S regulatory particles, responsible for 
recognizing, unfolding, and translocating polyubiquitinated proteins into the inner degradative chamber of the 
20S2. This is a ~700 kDa cylindrical macromolecular machine formed by four overlapping heptameric rings, con-
sisting of α (the outer rings) or β (the inner rings) subunits3. Normally, the hydrolyzing activity is yielded by 
subunits β5, β2, and β1 of the 20S proteasome. However, cells of the immune system or exposed to proinflamma-
tory cytokines are induced to express three additional homologous subunits (β5i, β2i, β1i), which replace their 
constitutive counterparts in newly synthesized and shorter-lived immunoproteasomes4. In principle, proteas-
omes can hydrolyze the C-terminal amide bond of every amino acid but proline5; however, proteolytic activi-
ties assessed by means of short fluorogenic peptides identify three defined hydrolyzing preferences: trypsin-like 
(i.e. hydrolysis at the C-terminus of basic residues, β2/β2i), chymotrypsin-like (i.e. hydrolysis at the C-terminus 
of hydrophobic residues, β5/β5i), and caspase-like activity (i.e. at the C-terminus of acidic residues, β1/β1i). A 
variety of low molecular weight inhibitors of the proteolytic sites of 20S have been identified that can enter cells 
1Department of Veterinary Sciences, University of Turin, Largo P. Braccini 2, 10095, Grugliasco, Turin, Italy. 2Medical 
Oncology Unit, Ospedale U. Parini, Viale Ginevra 3, 11100, Aosta, Italy. 3San Raffaele Scientific Institute, Division 
of Genetics and Cell Biology, Via Olgettina 60, 20132, Milan, Italy. 4Thoracic Surgery Unit, Ospedale U. Parini, Viale 
Ginevra 3, 11100, Aosta, Italy. 5Medical Oncology, Azienda Ospedaliera SS Antonio e Biagio e C Arrigo, Via Venezia 
16, 15121, Alessandria, Italy. Correspondence and requests for materials should be addressed to P.C. (email: paolo.
cascio@unito.it)
Received: 20 September 2017
Accepted: 4 December 2017
Published: xx xx xxxx
OPEN
www.nature.com/scientificreports/
2Scientific REPORtS | 7: 17626  | DOI:10.1038/s41598-017-17977-9
and block proteasomal protein degradation6. These agents proved essential for investigating the biological role 
of the ubiquitin-proteasome system and led to the discovery of diverse key regulatory functions of this pathway. 
Furthermore, since proteasome inhibitors (PIs) also induce adaptive and maladaptive responses (e.g. the unfolded 
protein and heat-shock responses), showing previously unpredicted specificity against certain tumor cells, they 
became the paradigm of negative proteostasis regulators in cancer therapy7.
The anti-cancer use of PIs stemmed from the original observation of their remarkable toxicity against a variety 
of cancer cells at doses that had little or no toxicity against normal, non-transformed cells8. Further studies and 
clinical trials allowed the rapid approval of the modified boronic dipeptide bortezomib (Btz, PS-341 or Velcade®) 
for the treatment of multiple myeloma (MM)9 and refractory mantle cell lymphoma10. Encouraging results were 
also reported on other hematological and solid cancers11,12. Moreover, the anti-tumor activity of five second gen-
eration PIs is currently being evaluated in dedicated clinical trials13. In the case of MM, the accumulation of poly-
ubiquitinated proteins is an established mechanism of PI-induced apoptosis14,15. Such a condition, referred to as 
proteasome stress16,17, in plasma cells is particularly aggravated by the extremely high load of protein degradation 
imposed by large-scale immunoglobulin production, which makes the apoptotic threshold particularly low18–20. 
This load-versus-capacity model offers an explanation for the exquisite sensitivity of malignant plasma cells to 
PIs21, and also for the variability observed among different MM cell lines and primary tumors, which differ in 
both proteasome capacity and degradative workload18. Furthermore, demonstrating cause-effect relationships, 
increasing proteasome expression18 and reducing protein synthesis21 independently increased bortezomib resist-
ance. Whether and to what extent the load-versus-capacity model may also contribute to explain PI responsive-
ness of other cancers, and particularly solid tumors, is currently unknown.
Malignant pleural mesothelioma (MPM) is a highly deadly cancer arising from the mesothelium of serous 
cavities following exposure to asbestos22. Circa 3,000 new MPM cases are diagnosed yearly in the United States, 
with ~250,000 deaths predicted to be caused by MPM in the next 30 years in occidental Europe23,24. Although 
measures have been implemented to limit further exposure to asbestos, the long latency of MPM generated a 
strikingly increasing incidence of this malignancy. MPM is normally intractable by to local therapies and typi-
cally progresses with a median overall survival of 12–36 months for localized illness and only 8–14 months for 
advanced disease25. The currently available chemotherapeutic drugs are poorly active against MPM, with usual 
single-agent response rates of ≤20%26, and first-line radiation therapy is generally ineffective27. Combination 
therapy with pemetrexed and cisplatin is the current standard first-line treatment28. However, median survival 
on this regimen is below 1 year, with <50% response rate. Notable, a randomized phase 3 trial recently reported 
a significant gain in overall survival (median 18.8 vs. 16.1 months) in MPM patients treated with bevacizumab in 
addition to the standard pemetrexed and cisplatin regimen29. Moreover, no approved standard of care for patients 
who have relapsed is available, since several trials have failed to show useful activities in a second-line setting30. 
Hence, identifying and developing new treatments for MPM is an unmet need.
Although some molecular profiling studies of malignant mesothelioma identified the ubiquitin-proteasome 
system (UPS) as a potential therapeutic target31–33, several others could not establish any significant correlation 
between clinical and/or anatomo-histological features of MPM and alterations of the proteasome proteolytic 
pathway34–41. Notwithstanding, the first-in-class PI bortezomib demonstrated promising anti-tumoral activity in 
both in vitro and in vivo preclinical models of MPM. Specifically, bortezomib was shown to induce cytotoxicity, 
cell cycle arrest, and apoptosis in several primary patient-derived and immortalized MPM cell lines, while sparing 
normal mesothelial cells42–44. The effector mechanisms of such toxicity are poorly understood, with an intricate 
network of pro- and anti-apoptotic factors possibly implicated45–48. These results provide the rationale to clinically 
evaluate the effect of bortezomib, alone or in combination with cisplatin, against MPM49,50. However, only modest 
therapeutic benefits were observed. In particular, data from a multicenter Phase II study of bortezomib as mon-
otherapy in an unselected population of MPM patients demonstrated a poor (5%) response rate, implying that 
inherent mechanisms of resistance protect primary tumors49. Identifying the molecular bases of the differential 
sensitivity of MPM cells to proteasome inhibition is, therefore, critical to design novel pharmacologic strategies 
aimed at increasing responsiveness to bortezomib, alone or in therapeutic combinations. To this end, we hereby 
challenged the load-versus-capacity model in a panel of four human MPM cell lines characterized by differential 
apoptotic sensitivity to bortezomib.
Results
Human MPM cell lines show differential sensitivity to the pro-apoptotic effects of bortezomib. 
In an effort aimed at verifying whether different MPM cell lines display differential sensitivity to apoptosis 
triggered by proteasome inhibition, we initially tested the biological effects of bortezomib on a panel of four 
human MPM clones. In particular, MSTO-211H, REN, MM98, and MMB cell lines were treated with increas-
ing amounts of bortezomib and apoptosis was measured after 48 hours by FACS assessment of annexin V and 
propidium iodide positive cells. As shown in Fig. 1, all clones displayed a marked dose-dependent susceptibility 
to the pro-apoptotic effects of bortezomib in the nanomolar range. However, the sensitivity to the inhibitor of the 
four cell lines clearly differed. In particular, MM98 and REN cells displayed EC50 values for bortezomib-induced 
apoptosis of 17 and 22 nM respectively, while the MSTO-211H line was relatively more resistant with an EC50 of 
60 nM. The MMB line was characterized by an intermediate sensitivity (EC50 33 nM; Table 1). Thus, we demon-
strated that the aforementioned MPM lines are characterized by a well-defined differential sensitivity/resistance 
to bortezomib and are therefore suitable for investigating the molecular mechanisms responsible for the different 
susceptibility of MPM cells to apoptosis caused by proteasome inhibition.
Different sensitivity of MPM clones to bortezomib correlates with proteasome activity. To 
assess whether in MPM, as in the paradigmatic PIs-sensitive cancer MM, enhanced susceptibility towards cyto-
toxic effects of bortezomib correlates with lower overall potential proteasomal proteolytic capacity, we measured 
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the three main peptidase activities of 26S proteasomes in cellular extracts from the four MPM clones by specific 
fluorogenic substrates in the presence of ATP. With this method proteasome cleavage specificities can be selec-
tively assessed in crude extracts, avoiding time-consuming and laborious chromatographic purifications, since 
the contribution of non-proteasomal enzymes is determined by highly specific inhibitors of proteasome active 
sites51. By this approach, we could demonstrate that rates of fluorogenic peptides hydrolysis clearly differ between 
the MPM lines (Fig. 2A). More importantly, the strongly Btz-sensitive and relatively BTZ-resistant MM98 and 
MSTO-211H lines displayed, respectively, lower and higher 26S chymotrypsin-like and trypsin-like activities, 
which are the main proteasomal cleavage specificities and the rate limiting activities for protein turnover52,53. 
Moreover, for all MPM clones a clear, direct correlation between proteasome chymotrypsin- and trypsin-like 
activities and resistance to apoptosis induced by bortezomib was seen (Fig. 2B), strongly suggesting that the size 
of the proteasomal compartment contributes to the sensitivity to PIs in mesothelioma cells. Only for the minor 
caspase-like activity could a clear positive correlation with Btz-EC50 values of the corresponding MPM lines not 
be established (Fig. 2B).
Loss of concerted expression of proteasomal subunits in MPM clones. To investigate the reasons 
for the difference in proteasome activities of MPM clones in more detail at the molecular level, we measured the 
expression levels of several proteasome subunits by western blot analysis. In this regard, it is worth noting that the 
steady-state levels of mature β-subunits, which are subjected to autocatalytic cleavage upon assembly to generate 
the active form, are directly responsible for proteasome peptidase activities54. Unexpectedly, the expression pat-
terns of the catalytic β-subunits of both constitutive and immuno proteasomes was complex and highly variable 
between MPM lines (Fig. 3A). In fact, indicative of a loss of the regulatory mechanisms that normally ensure 
concerted expression of the catalytic subunits of constitutive and immuno proteasomes, each clone showed an 
individual pattern of content of β-subunits, with some antigens clearly up-regulated and others down-regulated, 
with no clear delineations between the different lines (Fig. 3B). Similarly, the steady-state levels of the α-subunits 
also appeared variable and not concertedly regulated in each MPM line, although in this case expression lev-
els seemed concordantly reduced in MM98 cells, which are characterized by lower proteasome activity (Fig. 2). 
However, α-subunits do not necessarily reflect assembled, functional proteasomes, since they also include the 
pool of free intracellular subunits54.
More Btz-sensitive MPM lines display higher levels of proteasome stress. A reduced proteasomal 
compartment may not be effectively suited to cope with the degradative needs of the cell. As a consequence of 
the resulting unbalance in the load-versus-capacity ratio, cells are expected to experience a higher basal level of 
proteotoxic stress that, in turn, lowers their intrinsic apoptotic threshold. To verify this scenario, we therefore 
Figure 1. Effects of bortezomib on the viability of malignant pleural mesothelioma cell lines. MM98, REN, 
MMB, and MSTO-211H cells were treated with increasing concentrations of bortezomib and apoptosis was 
measured after 48 hours by FACS of annexin V and propidium iodide positive cells, and expressed as variation 
vs. untreated cells. Values are mean ± SE of three independent experiments. R2 for a sigmoidal dose-response 
curve ≥0.9 in all cases.
Cell line EC50 Btz (nM)
MM98 16.9 ± 1.7
REN 22.1 ± 1.4
MMB 33.4 ± 2.0
MSTO-211H 60.1 ± 8.6
Table 1. Differential sensitivity of MPM cell lines to bortezomib. The Malignant Pleural Mesothelioma cell lines 
MM98, REN, MMB, MSTO-211H were treated for 48 hours with increasing concentrations of bortezomib (Btz) 
and the proportion of apoptotic (annexin V + propidium iodide-) cells was measured by FACS. The indicated 
EC50 are an average of 3 independent experiments ± SE.
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looked for signs of proteasomal sufferance in the MPM lines by assessing the intracellular levels of free and 
polymerized ubiquitin. As shown in Fig. 4A, western blotting analysis unambiguously demonstrated that the 
more Btz-sensitive MM98 and REN clones are characterized by a significantly lower content of unbound ubiqui-
tin compared to the relatively more resistant MMB and MSTO-211H cell lines (Fig. 4B). This deficiency of free 
ubiquitin reflects its role in building polyubiquitin chains, which, in fact, were greatly accumulated in the more 
Btz-sensitive clones (Fig. 4C).
To investigate these findings, indicating saturation of proteasome proteolytic capacity with consequent 
accumulation of undegraded substrates in MPM cells that were more vulnerable to bortezomib, we evaluated 
polyubiquitinated proteins at the single cell level by confocal immunofluorescence microscopy. To this aim, we 
used FK2, an antibody that recognizes different types of polyubiquitin chains55 and therefore it is particularly 
well-suited to detect all potential proteasome substrates. In fact, several recent evidences indicate that not only 
the canonical lysine-48 linked polyubiquitin chains but also other alternative ubiquitin linked chains support 
degradation by the 26S proteasome56,57. In line with the western blot data, this analysis revealed strong basal 
accumulation of polyubiquitinated proteins in REN and MM98 cells with a discrete cytosolic and nuclear pattern, 
clearly exceeding the signal present in MMB and MSTO-211H cells (Fig. 5). Subsequent quantification and sta-
tistical analysis of FK2-dependent fluorescence confirmed that basal accumulation of polyubiquitinated proteins 
differed substantially in all four MPM clones (Fig. 6A). Most importantly, the fluorescence intensity associated to 
polyubiquitinated proteins negatively correlated both with the main functional activities of 26S (Fig. 6B) and the 
EC50 of the corresponding MPM clone for the pro-apoptotic effect of bortezomib (Fig. 6C), clearly indicating a 
role for overload of proteasomal degradative capacity in determining cellular susceptibility to PIs.
Discussion
Previous studies have shown that bortezomib and other PIs exhibit significant anti-tumoral activity in preclinical 
models of MPM both in vitro and in vivo42–44,58,59. Disappointingly, however, this efficacy was not successfully 
translated in clinical activity due to either primary and/or acquired resistance49,50. In an effort aimed at iden-
tifying the mechanisms of the different intrinsic sensitivities of MPM cells to cytotoxicity induced by protea-
somal inhibition, we initially assessed the pro-apoptotic effects of bortezomib in a panel of four human MPM 
cell lines. In accordance with published data, this analysis revealed that all four MPM clones tested displayed 
pronounced apoptotic vulnerability to bortezomib, with EC50 values comparable to those determined by the 
Figure 2. Reduced proteasome activity in MPM cell lines with increased sensitivity to bortezomib. (A) 
Chymotrypsin-like, trypsin-like, and caspase-like specific activities of proteasomes were assessed in cell 
extracts as described in the Materials and Methods and expressed on a per-cell basis. Data are the mean of 
six independent measurements. **P < 0.01. (B) Correlations of 26S proteasome peptidase activities and EC50 
values relative to the apoptotic effect of bortezomib in MPM cell lines.
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same experimental approach for different cell lines of human multiple myeloma, the paradigmatic proteasome 
inhibitors responsive cancer21. Crucially, however, the primary sensitivity of these MPM lines to bortezomib 
varied, with MM98 and REN cells characterized by higher vulnerability to the drug (EC50 values of 17 and 22 nM, 
respectively), while the MSTO-211H line was relatively more resistant (EC50 of 60 nM) and the MMB clone hall-
marked by intermediate susceptibility (EC50 of 33 nM). The finding that these mesothelioma cell lines are not 
equally responsive to the cytotoxic effects of bortezomib prompted us to investigate the molecular mechanisms of 
their different intrinsic sensitivity to PIs. In fact, primary resistance to bortezomib represents a crucial therapeutic 
challenge not only for solid tumors like MPM, but also for prototypical PIs-responsive hematological malignan-
cies. More than 50% of MM patients, for example, fail to respond to bortezomib and the basis of this different 
intrinsic responsiveness remains elusive. We18,21 and others60 have recently shown that exquisite apoptotic sensi-
tivity of both primary or immortalized MM cells arises from exuberant synthesis of abnormal proteins impinging 
on a reduced proteasome pool. The resulting saturation of cellular proteolytic capacity (a condition referred to as 
proteostenosis) has profound consequences for cell viability and tumor chemosensitivity21.
The present study is, to the best of our knowledge, the first documenting that different levels of basal pro-
teasome stress, intended as a situation of precarious equilibrium, characterized by lack of overt signs of cell suf-
ferance (e.g. cell cycle arrest), but deeply affecting the capacity of the cell to successfully cope with additional 
stress, underlies the intrinsic apoptotic sensitivity to bortezomib for a solid cancer such as pleural mesothelioma. 
Under normal conditions mammalian cells are capable of adapting their proteasome content to proteolytic needs 
Figure 3. Steady-state levels of catalytic β and non-catalytic α-subunits of constitutive and immunoproteasomes 
in MPM cell lines. (A) Cellular extracts from the MM98, REN, MMB, and MSTO-211H lines were resolved 
by SDS-PAGE and analyzed by western blotting with Abs to different proteasome catalytic β and non-catalytic 
α-subunits. Equal protein amounts (6 µg) were loaded in each lane, with α-tubulin serving as a loading control. 
*Unspecific band. All the blots were cropped according to their locations in the membrane in order to fit the 
size, see the original figures in the supplementary information. (B) Relative densitometric quantification of 
western blot bands shown in panel A normalized by the control loading signal.
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(through complex feedback loops involving the transcription factor NRF1, and the mTorc1 and ERK5 pathways), 
thus relieving proteasome stress, as demonstrated in several experimental settings61,62. However, as shown in 
many studies, cancer cells generally suffer from more stress than their benign counterparts, and are generally 
more reliant on stress adaptive pathways, making them less efficient at coping with additional stress, hence the 
model of non-oncogene addiction, which provides a rationale for targeting protein homeostasis or other stress 
adaptive pathways63. Consistent with this concept, the neoplastic cell lines (both in the case of MPM or MM) hall-
marked by an intrinsic, exquisite sensitivity to PI-induced cytotoxic effects, invariably show pathognomonic signs 
of proteasome stress (e.g. marked accumulation of polyubiquitinated conjugates at the expense of free monomeric 
ubiquitin), even in the absence of any other condition or stimulus that might negatively impinge on proteasome 
cellular content or activity. Although other mechanisms such as differential activities of ubiquitin-ligases or deu-
biquitinating enzymes might contribute to the increase in steady-state levels of ubiquitin-conjugates, the strong 
correlation between accumulation of polyubiquitinated substrates and low chymotrypsin-like and trypsin-like 
proteasome activities (that are rate limiting for degradation of proteins in vivo and in vitro52,53) strongly indicates 
that reduced proteasome levels and activities play a pivotal role in this process. In fact, in MPM, as already well 
documented for MM, enhanced levels of proteotoxic stress invariably correspond to a strong reduction of the 
cellular proteasome compartment. Indeed, the two MPM lines (MM98 and REN) displaying the lower overall 
26S activity were found to accumulate higher levels of polyubiquitinated proteins than the two lines (MMB and 
MSTO-211H) characterized by a higher proteasome content. Interestingly, our results show that proteasome lev-
els may vary greatly among different MPMs, with profound implications for the intrinsic capability of coping with 
cytotoxic stress, given the key role of the proteasome in integrating signals that control cell-cycle progression, 
Figure 4. Basal accumulation of polyubiquitinated proteins at the expense of the pool of free ubiquitin in MPM 
cell lines more sensitive to bortezomib. (A) 15 µg of cellular extracts from the MM98, REN, MMB, and MSTO-
211H lines were incubated with anti-ubiquitin (Ub) Ab. For each clone, data from three independent cell 
extracts are shown. Samples derive from the same experiment and that gels/blots were processed in parallel. The 
blots were cropped according to their locations in the membrane in order to fit the size, see the original figures 
in the supplementary information. (B) Densitometric quantification of mono-ubiquitin bands shown in panel 
A. **P < 0.01. (C) Polyubiquitinated proteins (poly-Ub, 5 µg of cellular extract) were resolved as a smear in an 
12% SDS-Page gel, while free Ub was separated in an 18% gel.
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apoptosis, and metabolism. Accordingly, chymotrypsin-like and trypsin-like proteasome activities inversely cor-
relate with the sensitivity to bortezomib of MPM lines, indicating that reduction of the proteasome cellular pool 
represents a crucial determinant of proteotoxic stress that predisposes mesothelioma cells to the pro-apoptotic 
effects of PIs. Importantly, bortezomib mainly targets chymotrypsin-like proteasomal activity, while discordant 
results were reported concerning its effects toward trypsin-like sites11,64. However, it is worth noting that in vivo 
both bortezomib and other PIs exert their toxic effects by blocking catabolism of full length proteins, whose rates 
of hydrolysis are determined by the concomitant and coordinated action of all three proteasome active sites, 
acting through a complex (and not yet completely understood) network of allosteric functional interactions65,66.
Moreover, western blot analysis of the steady-state levels of several proteasome subunits revealed that the 
MPM cells analyzed in our study have lost the standard, concerted expression of all three catalytic β-subunits 
of constitutive or immuno proteasomes. On the contrary, each MPM clone shows a specific and individual pat-
tern of catalytic β-subunit expression, indicative of a loss of the regulatory mechanisms that under physiological 
conditions ensure coordinated expression of active β-subunits, with the purpose to adapt proteasome capacity to 
cellular needs so as to maintain homeostasis61. Such dysregulated expression patterns may be a consequence of 
genotoxic stress typical of neoplastic cells, and are likely to account for the difference in the proteasome activity 
between MPM cell lines that our study unveiled. In fact, reduced expression of individual catalytic subunits and 
Figure 5. Immunofluorescence microscopy of polyubiquitinated proteins in MPM cell lines. Cells were stained 
with FK2 antibody, which specifically recognizes poly-ubiquitin chains, and analyzed by confocal microscopy 
in three independent experiments. Nuclei labelled red by propidium iodide (PI); size bar: 50 μm lower 
magnification (left) and 10 μm higher magnification (right). Representative images. Cell area (µ2), mean ± St. 
dev.: MM98 108 ± 11, REN 117 ± 9, MMB 93 ± 12, MSTO-211H 110 ± 8.
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conceivable formation of non-standard mixed proteasomes containing β-subunits of both immuno and constitu-
tive proteasomes may substantially affect overall proteasome enzymatic efficiency67. Of note, loss of the concerted, 
physiological expression of all proteasome subunits is likely to account for the inability of several DNA microar-
rays studies to demonstrate a crucial role of the proteasome proteolytic pathway in the biology and pathogenesis 
of MPM34–41. These results emphasize the need to integrate microarrays expression data with functional measure-
ments of proteasome enzymatic activities.
Of great interest, our study revealed a striking positive correlation between high levels of polyubiquitinated 
conjugates in MPM cell lines and primary sensitivity to the pro-apoptotic effects of bortezomib, which strongly 
suggests a cause-effect relationship. In fact, the more Btz-sensitive MM98 and REN lines displayed high levels 
of basal proteasomal stress indicative of a reduced efficiency of adaptive strategies, including induction of pro-
teasome biogenesis (so-called Proteasome stress response)16,17, which might relieve the proteostatic imbalance 
experienced by these MPM clones. Of note, the stressful condition revealed by basal accumulation of endogenous 
ubiquitin conjugates is still compatible with apparently normal cell functions, implying regular turnover of key 
proteasomal substrates (e.g. cyclins). However, this precarious equilibrium can be easily pushed towards a toxic 
collapse of proteostasis by further compromising the proteolytic route at doses of PIs that are lower than those 
Figure 6. Basal accumulation of polyubiquitinated proteins inversely correlates with proteasome activity 
and with intrinsic resistance of MPM clones to the pro-apoptotic effects of bortezomib. (A) Different levels of 
polyubiquitin conjugates in MPM cell lines. Quantification of the FK2-dependent fluorescence in MPM cells 
was performed using Image J software (n ≥ 100 cells in ≥ 16 distinct fields). ***P < 0.001. Inverse correlation 
between levels of polyubiquitinated proteins in MPM clones and 26S proteasome chymotrypsin- and trypsin-
like activities (B) and EC50 values relative to apoptotic sensitivity to bortezomib (C).
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required to achieve the same result in cells that, like MSTO-211H (and to a lesser extent MMB), are characterized 
by a more-favorable load-versus-capacity ratio. Importantly, saturation of the proteasomal proteolytic route may 
stabilize pro-apoptotic effectors, such as the Bcl-2 homology domain 3 (BH3)-only proteins Bim and Noxa and 
the mitochondrial outer membrane permeabilizers BAX/BAK, or abrogate activity of survival factors like NF-kB, 
which are all known to play a pivotal role in modulating the sensitivity of MPM cells to bortezomib44,45,47,49,68. So 
far, it has been generally assumed that the load-versus-capacity model may account for the exquisite sensitivity 
to PIs of MM and other professional secretory cells that are intrinsically predisposed to saturation of the protea-
somal degradative route due to their overwhelming rates of protein synthesis. Our data, on the contrary, suggest 
that a compromised proteostatic equilibrium, arising at least in part from a reduced proteasome pool, might be a 
typical hallmark of PIs-sensitive cancers in general. Although further studies will be required to fully understand 
the molecular mechanisms of this proteostatic unbalance in MPM and possibly in other PIs-responsive solid can-
cers, it is possible that the high levels of genotoxic stress typically experienced by tumor cells, with the consequent 
enhanced generation of mutated/abnormal polypeptides requiring extremely fast degradation69, accompanied 
by a reduced efficiency of appropriate adaptive strategies counteracting this stressful and potentially harmful 
condition, might underlie the basal proteotoxic stress seen in our study in MPM clones that are more sensitive to 
bortezomib.
Our results documenting that an unfavorable load-vs-capacity ratio represents a critical determinant of apop-
totic sensitivity and underlies vulnerability to bortezomib not only for the prototypical PIs-responsive hema-
tological cancer multiple myeloma, but also for an extremely recalcitrant solid tumor like MPM, potentially 
provide a framework for identifying indicators of responsiveness to PIs and for improving their clinical efficacy. 
Conceivably, our data indicate that assessment of proteasome stress and capacity in MPM patients might repre-
sent a potential predictor of individual responsiveness to bortezomib with both prognostic and therapeutic value. 
Moreover, pharmacological strategies aimed at exacerbating the proteotoxic stress experienced by MPM cells are 
predicted to lower their intrinsic threshold to apoptosis triggered by PIs and therefore substantially increase their 
efficacy against this malignancy.
Methods
Cell lines. Human malignant pleural mesothelioma (MPM) cell lines were generously provided by Dr. S. 
Biffo (University of Milan, Milan, Italy) (MM98) and Dr. G. Gaudino (University of Hawaii, Honolulu, HI, USA) 
(MMB, MSTO-211H, REN). MSTO-211H were maintained in RPMI1640 containing 10% fetal bovine serum 
(FBS), L-glutamine, and antibiotics; REN and MM98 in DMEM containing 10% FBS, L-glutamine, and antibiot-
ics; MMB in nutrient mixture F-12 Ham supplemented with 110% FBS, L-glutamine, and antibiotics. All MPM 
cell lines were cultured at 37 °C in an humidified incubator in an atmosphere of 5% CO2. Under these growth 
conditions, the doubling time for all MPM clones was ~24 h. All cell culture reagents were purchased from Sigma-
Aldrich (St. Louis, MO, USA).
Flow-cytometric analyses of apoptosis. Cells were treated with bortezomib (Millennium 
Pharmaceuticals, Cambridge, MA, USA) as indicated, harvested, stained with FITC-conjugated Annexin V (1 μg/
ml) and propidium iodide (2.5 μg/ml) according to the manufacturer’s instructions, and analyzed by FACScalibur 
(BD Biosciences, Franklin Lakes, NJ, USA) as described18,19,21.
Proteasome activity assays. Proteasome activity was assessed in MPM crude extracts using fluoro-
genic peptides according to a method that avoids long and laborious chromatographic purification of 26S par-
ticles51. Accordingly, proteasome-specific peptidase activities were assayed by monitoring the production of 
7-amino-4-methylcoumarin (amc) from the following fluorogenic peptides (Bachem, Bubendorf, Switzerland): 
100 μM Suc-LLVY-amc (for chymotrypsin-like), 500 μM Bz-VGR-amc (for trypsin-like), and 100 μM 
Ac-YVAD-amc (for caspase-like activity) in 20 mM Tris-HCl (pH 7.5), 1 mM ATP, 2 mM MgCl2, and 0.2% bovine 
serum albumin (BSA). Two of these substrates (Suc-LLVY-amc and Suc-YVAD-amc) were used at a concentra-
tion highly exceeding their Km value for the relative proteasome catalytic β-subunit, and therefore hydrolysis rates 
were assessed at Vmax. The third substrate (Bz-VGR-amc) has a lower affinity for β2/β2i subunit and was used at a 
higher concentration to approach its Vmax of hydrolysis (Not shown). Reactions were started by adding an aliquot 
of cellular extract, and the fluorescence of released amc (excitation, 380 nm; emission, 460 nm) was monitored 
continuously at 37 °C with a Carry Eclipse spectrofluorometer (Varian, Palo Alto, CA, USA). Background activity 
(caused by non-proteasomal degradation) was determined by addition of the PI epoxomicin (Sigma-Aldrich, St. 
Louis, MO, USA) for chymotrypsin-like activity, MG132 (Calbiochem, San Diego, CA, USA) for caspase-like 
activity and β-lactone (Enzo Life Sciences, Farmingdale, NY, USA) for trypsin-like activity, each used at a final 
concentration (2 μM, 10 μM, and 20 μM, respectively) known to completely suppress the relative proteasomal 
peptidase activity without affecting other proteases with the same cleavage specificity6. Assays were calibrated 
using standard solutions of free fluorophore, and reaction velocities were calculated from the slopes of the initial 
linear portions of the curves. Substrate consumption at the end of incubation never exceeded 1%.
Immunoblot analyses. Immunoblot analyses of α and β-subunits of constitutive and immuno proteas-
omes, α-tubulin, free ubiquitin and polyubiquitinated proteins were performed as previously described21,54. 
Briefly, extracts were resolved by 18% (for free ubiquitin) or 12% (for polyubiquitinated conjugates and all other 
antigens) SDS-PAGE gel and transferred on Nitocellulose (Sigma-Aldrich, St. Louis, MO, USA, for polyubiq-
uitinated conjugates) or Immobilon®-P (Merck Millipore, Darmstadt, Germany, for all other antigens) trans-
fer membranes. Nitrocellulose membrane was boiled for 5 min to unmask poly-Ub antigens and so make more 
sensitive and quantitative the immunoblot. The membranes were then incubated in blocking buffer (5% BSA, 
0.1%Tween-20 in 1 × PBS), followed by incubation with mAb anti-ubiquitin (P4D1, Santa Cruz Biotechnologies, 
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Santa Cruz, CA, USA), anti α-tubulin (T5168, Sigma-Aldrich, St. Louis, MO, USA), anti-α3, -α4, -α5 (MCP196, 
MCP79, MCP257, Enzo Life Sciences, Farmingdale, NY, USA), anti-β1, -β2, -β5, -β1i -β2i, -β5i (gift of Prof. S. 
Ferrone, Harvard Medical School, Boston, MA, USA). Bound antibodies were visualized using the ECL technique 
and bands were detected with Hyperfilm™ ECL™ (GE Healthcare). Densitometric analysis was performed with a 
VersaDoc 1000 Imaging System and Quantity One software (Bio-Rad, Hercules, CA, USA).
Immunofluorescence. MPM cell lines were seeded on poly-L-lysine-coated slides, fixed with 4% paraform-
aldehyde for 10 min at room temperature (RT), and permeabilized with PBS 0.1% Triton X-100 for 10 min at RT. 
Cells were then preincubated with PBS-1% normal goat serum (NGS) for 30 min at RT, incubated with mono-
clonal mouse anti-ubiquitin (clone FK2, 1/100; Enzo Life Sciences, Farmingdale NY, USA) diluted in PBS-1% 
NGS for 1 hour at RT, rinsed in PBS, and then stained with goat anti-mouse IgG Alexa Fluor 488 (1/200, Life 
Technologies, Paisley, UK) diluted in PBS-1% NGS for 1 hour at RT. After rinsing in PBS, cells were stained with 
propidium iodide for 5 min at RT (1/1000; Sigma-Aldrich, St. Louis, MO, USA), washed in PBS, and mounted 
with Vectashield mounting medium (Vector Laboratories, Burlingame, CA, USA). Images were acquired as 
single-stack images (capture images) at 40× water immersion with a confocal laser scanning microscope (TCS 
SP5, Leica Microsystems). Laser parameters were kept unchanged for all the different cell groups so that the 
detection of staining was maximal while avoiding pixel saturation. Quantitative analysis was performed by an 
operator unaware of the experimental group. Images were analyzed with ImageJ software (NIH, Bethesda, MD, 
USA) measuring cell area, mean gray value, and integrated density. More than 100 cells per group were counted 
and analyzed.
Statistical analysis. To compare average measurements of peptidase proteasomal activities, western blot 
densitometries, and immunofluorescence intensities, we adopted a non-parametric Mann-Whitney test, since 
preliminary Shapiro-Wilk tests have proven that data were not normally distributed. Data were graphically visu-
alized using box plots.
Data Availability. No datasets were generated or analyzed during the current study.
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